Overview

Interleukin-1 Blockade in Recently Decompensated Heart Failure

Status:
Completed
Trial end date:
2016-09-23
Target enrollment:
Participant gender:
Summary
The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Interleukin 1 Receptor Antagonist Protein